Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Relationship Between Depressive Symptoms and Cognitive Function in Non-Demented Older Adults Across Different Alzheimer’s Disease Biomarker Profiles
Aging, Dementia, and Behavioral Neurology
Aging and Dementia Posters (7:00 AM-5:00 PM)
080
To investigate cross-sectional associations between subclinical depressive symptoms and cognitive function across different clinical stages and ATN biomarker classifications (ß-amyloid [A], p-tau [T], and neurodegeneration [N]).

Evidence suggests an association between Alzheimer’s disease (AD)-associated pathologic changes and depressive symptoms.
Participants included 868 individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI) in two clinical stages: cognitively normal (CN) or amnestic mild cognitive impairment (aMCI) at baseline. Geriatric depression scale (GDS) was used to assess depressive symptoms.  ADNI neuropsychological composite scores were used to assess memory and executive function (EF). PET, CSF, and MRI were used to classify the study population to 3 biomarker profiles: Normal (A-T-N-), AD-Pathology (A+T±N±), and Suspect Non-AD Pathology (SNAP; A-T±N- or A-T-N±). Multivariate regression models were used to investigate associations between GDS and cognitive domain scores.

Participants had a mean age of 72.7 (SD =6.85) years; 46.3% were female. Higher GDS scores were significantly associated with lower memory (β=-.085, p<.001) and EF scores (β=-.095, p<.001) in the entire sample. When the population was divided by clinical stage, higher GDS was significantly associated with worse EF in the aMCI subgroup (β=-.051, p=.038). When participants were classified by biomarker profile, GDS was negatively associated with memory and EF in both AD-pathology (memory: β=-.093, p<.001; EF: β=-.083, p=.003) and SNAP (memory: β=-.092, p=.005; EF: β=-.127, p=.001) subgroups but not in the normal subgroup. When participants were classified by both clinical stage and biomarker profile, higher GDS was associated with improved memory and EF in the CN group with normal biomarkers (memory: β=.097, p=.041; EF: β=.180, p=.012).  In the aMCI group with normal biomarkers, higher GDS was associated with worse EF (β=-.115 p=.019). 
The association between subclinical depressive symptoms and cognitive function is highly influenced by ATN biomarker profile and is stronger in groups with AD pathology or SNAP. 
Authors/Disclosures
Mariel Rubin-Norowitz
PRESENTER 		Mariel Rubin-Norowitz has nothing to disclose.
Richard B. Lipton, MD, FÂ鶹´«Ã½Ó³»­ (Albert Einstein College of Medicine) Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.
Kellen Petersen (Albert Einstein College of Medicine) No disclosure on file
Ali Ezzati, MD (University of California, Irvine) The institution of Dr. Ezzati has received research support from NIA. The institution of Dr. Ezzati has received research support from Alzheimer's Association. The institution of Dr. Ezzati has received research support from Cure Alzheimer's Fund.